Study of Sitravatinib + PD-(L)1 Checkpoint Inhibitor Regimens in Urothelial Carcinoma
Status:
Recruiting
Trial end date:
2022-09-30
Target enrollment:
Participant gender:
Summary
The study will evaluate the clinical activity of PD-(L)1 Checkpoint Inhibitor regimens in
combination with the investigational agent sitravatinib in patients with advanced or
metastatic urothelial carcinoma.